Diligence memo · auto-generated · as of July 2, 2026
Ascendis Pharma A/S
Ascendis Pharma A/S looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Ascendis Pharma A/S operates in Pharmaceuticals, based in HELLERUP.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ascendis Pharma A/S has raised $60M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $60M on 2014-11-24.
Most recent recorded round closed around 2014-11-24.
Valuation (modeled)modeled
Provath models Ascendis Pharma A/S at approximately $2.1B (range $195M–$5.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.02× the median modeled value of Series C Pharmaceuticals companies in 2013–2015 (19 peers) — value vs value, same stage and era. Within the normal band (102% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 11.6 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 84% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Bellicum Pharmaceuticals, Inc, Paratek Pharmaceuticals Inc, Turing Pharmaceuticals AG, Seres Health, Inc., Syndax Pharmaceuticals Inc.
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.